COVID-19, Stress, Vaccines, and Your Immune System | Prostate Cancer Foundation
If you’ve felt a higher level of stress over the past year, you’re not alone. One study found that earlier in the pandemic, stress, depression, and
Related Articles
APCCC 2024: Management of Frail Patients with mHSPC
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Management of Frail Patients with mHSPC, M1 disease, abiraterone, prednisolone, abiraterone plus prednisolone, androgen deprivation…
APCCC 2024: Management of Patients with mHSPC and Early Progression on Combination Therapy
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), mHSPC and early progression on combination therapy, androgen deprivation therapy (ADT), abiraterone, enzalutamide, apalutamide, darolutamide,…
APCCC 2024: Genomic Classifiers and Artificial Intelligence as Predictors for Treatment Benefit
APCCC 2024 advanced prostate cancer, use of genomic classifiers and artificial intelligence tools as predictors of treatment benefit in prostate cancer patients, prostate cancer mortality,…
APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break?
APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent…
APCCC 2024: Update on the IRONMAN Project
APCCC 2024 update on the IRONMAN project, IRONMAN Executive Committee, treatment of advanced prostate cancer, Engaging Men in Patient Reported Outcomes, PROfound study, abiraterone, enzalutamide,…
APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better?
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression,…
APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”?
APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,
APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Surgery as Radical Local Treatment (As Part of a Multimodality Approach)
APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial,…
APCCC 2024: Radiation Therapy Schedules and Fields for High-Risk and Locally Advanced Prostate Cancer
APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic…
APCCC 2024: Should the Primary Be Treated in Synchronous High-Volume mHSPC
APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.